Table 4.
Ongoing studies of immunotherapy in gastrointestinal stromal tumors.
| Study number | Phase | Description |
|---|---|---|
| Association of anti-PD(L)-1 and anti-CTLA-4 antibodies | ||
| NCT02880020 | Phase II | Nivolumab +/-ipilimumab after progression under imatinib |
| NCT02500797 | ||
| NCT02834013 | ||
| NCT02982486 | ||
| Association of anti-PD-1 antibodies and IDO inhibitors | ||
| NCT03291054 | Phase II | Pembrolizumab +/- epacadostat after progression under imatinib |
| Association of TKI and anti-PD(L)1 antibody | ||
| NCT04258956 | Phase II | Axitinib + avelumab after progression under imatinib |
| NCT01738139 | Phase I | Imatinib + ipilimumab in tumors with a c-kit mutation |
| NCT03609424 | Phase I/II | Imatinib + PDR001 |
| Bispecific T Cell Engagers antibodies (BITEs) | ||
| NCT03411915 | Phase I | XmAb18087 (bispecific antibody against anti-SSTR2 et CD3) |